The Antibody Society

the official website of the antibody society

An international non-profit supporting antibody-related research and development.

  • LOG IN
  • BECOME A MEMBER
  • About
    • Mission & Activities
    • Board of Directors
    • Our Staff & Volunteers
    • The Antibody Society’s Standing Committees
      • AIRR Community Committee
      • Communication & Membership Committee
      • Initiatives Committee
      • Meetings Committee
    • Sponsors & Partners
  • Society meetings
    • Biopharmaceutical Informatics Symposium
    • Harnessing Cytokines for Cancer Immunotherapy Symposium
    • Emerging Cancer Therapies Leveraging Gamma-Delta Effector T cells Symposium
    • Emerging Immunotherapeutics for Ovarian Cancer Symposium
    • AIRR Community Meetings
    • Antibody Engineering & Therapeutics (US) 2022
      • 2020 Antibody Engineering & Therapeutics
      • 2019 Antibody Engineering & Therapeutics
      • 2018 Antibody Engineering & Therapeutics
      • What is INN a Name?
        • INN issue updates
    • Antibody Engineering & Therapeutics Europe 2022
    • FOCIS Symposia
  • AIRR Community
    • AIRR News
    • AIRR Publications
    • AIRR Meetings
      • AIRR Community Meeting VI: “Exploring New Frontiers”
      • AIRR Community Meeting V: “Zooming in to the AIRR Community”
      • AIRR Community Meeting V Pre-Meetings
        • AIRR-seq in the Pandemic
        • AIRR-seq Biological Standards and Workflows
      • AIRR Community Special Event: “Response to COVID-19”
      • AIRR Community Meeting IV: “Bridging the Gaps”
      • AIRR Community Meeting III
        • Day 1
        • Day 2
        • Day 3
        • Day 4
      • AIRR Community Meeting II
      • AIRR Community Meeting I
    • AIRR Community Working Groups
      • Biological Resources Working Group
      • Common Repository Working Group
      • Diagnostics Working Group
      • Germline Database Working Group
      • Legal and Ethics Working Group
      • Software Working Group
      • Standards Working Group
    • AIRR Community Sub-committees
      • Communications Sub-committee
      • Executive Sub-committee
      • Inferred Allele Review Committee
      • Meetings Sub-committee
    • AIRR Data Commons
    • AIRR Community Calendar
    • AIRR Community Webinar Series
    • On AIRR – An AIRR Community Podcast
    • AIRR Community Resources
    • AIRR Community Service Prize 2022
  • Members only
    • Login
    • Note to members
    • James S. Huston Antibody Science Talent Award
      • 2020 James S. Huston Antibody Science Talent Award Recipient
      • JSH Award Criteria
    • Research Competitions
      • Research Competition Winners
    • Science Writing Competition
      • Science Writing Competition Winners
    • Member discount codes
    • Antibodies in early-stage studies
    • Presentations
  • Upcoming meetings
  • Web Resources
    • Society Publications
    • Antibody News
    • Antibody therapeutics approved or in regulatory review in the EU or US
      • Antibody therapeutics product data
    • Antibodies in late-stage clinical studies
    • Research Resources
    • Education Resources
  • Career Center
    • Career Shorts
  • Learning Center
    • Upcoming Webinars
    • Snakebite antivenoms: Global challenges and progress toward recombinant antibody therapeutics
    • Adaptive Immune Receptor Repertoires
    • Antibody Discovery & Development
    • Commercializing Antibody Therapeutics
    • Antibodies to Watch
    • Antibody Validation
  • COVID-19
    • Guide to “Coronavirus in the Crosshairs”
    • COVID-19 Biologics Tracker
    • Meeting Report: The Diagnostic Landscape for COVID-19
You are here: Home / The Antibody Society’s meetings / Antibody Engineering & Therapeutics Europe 2020 / Antibody Engineering & Therapeutics Europe 2019

Antibody Engineering & Therapeutics Europe 2019

2019

Antibody Engineering & Therapeutics Europe
June 11-13, 2019
Postillion Hotel Amsterdam, the Netherlands

The Antibody Engineering & Therapeutics Europe meeting was a great opportunity for Society members to connect with industry and academic scientists and executives from Europe and around the world focused on antibody and protein therapeutic discovery and development. As always, The Antibody Society’s members designed the scientific program and acted as session Chairs.
Keynote speakers Jane Osbourn, Ph.D., (Vice President R&D and Site Leader of Medimmune) discussed antibody therapeutic developments, pipeline and progress at Medimmune and Hans Clevers, M.D., Ph.D., (Group Leader, Hubrecht Institute for Developmental Biology and Stem Cell Research and Professor of Molecular Genetics, University Medical Center Utrecht and Utrecht University) discussed Lgr5 stem cell-based organoids and their applications in cancer research. In addition, the meeting featured sessions on Turning Antibody Leads into Drugs, Recent Advances in Immuno-Oncology Approaches, Bioinformatics and Repertoires in Antibody Discovery and Development, Antibody Therapeutics for Autoimmune and Neurodegenerative Diseases, Clinical Developments in Antibody Therapeutics, and New Antibody Formats and Effector Functions.

The agenda is available here.

Photos from AE&TE 2019

Antibody Society Student/Postdoc Poster Competition Winner Roberta Lotti
Antibody Society Student/Postdoc Poster Competition Winner Amiram Sananes
Amiram Sananes with poster and award

Closeup of award from The Antibody Society
Roberta Lotti with poster
Networking session at The Society’s booth

Networking session at The Society’s booth
Networking session at The Society’s booth
Networking session at The Society’s booth

Networking session at The Society’s booth
Networking session at The Society’s booth

Networking session at The Society’s booth
Networking session at The Society’s booth

Twist Bioscientific booth

AE&TE programme
Michael Keenan at the podium

Kerry Chester, Session Chair and Antibody Society Board Member


2018


The Society’s inaugural Antibody Engineering & Therapeutics Europe meeting was held June 5-7, 2018, in Amsterdam. Members of the Society served as the Scientific Advisors and session Chairs. The meeting featured:

2 Half-Day Workshops

  • The Nuts and Bolts of Antibodies, moderated by Mahendra Deonarain, Ph.D., Chief Executive and Science Officer, Antikor Biopharma Ltd., United Kingdom
  • CAR-T & anti-CD3-based Bispecifics, moderated by Kerry A. Chester, Ph.D., Professor of Molecular Medicine, UCL Cancer Institute, University College London and President of The Antibody Society, United Kingdom and David Gilham, Ph.D., Vice President of Research and Development, Celyad S.A., Belgium.

4 Keynote Presentations

  • Frontiers of Immunotherapy, Clive R. Wood, Ph.D., Corporate Senior Vice President, Global Head of Discovery Research, Boehringer Ingelheim, Germany
  • T cell Recognition in Human Cancer, Ton N. Schumacher, Ph.D., Professor of Immunotechnology, Leiden University and Principal Investigator, The Netherlands Cancer Institute, The Netherlands
  • How Antibodies Trigger Cytotoxicity, Paul W.H.I. Parren, Ph.D., Professor, Department of Immunohematology and Blood Transfusion, Leiden University Medical Center, Sparring Biologics B.V., The Netherlands, and The Antibody Society Board of Directors member
  • Microbiome and Checkpoint Inhibitors in Immuno-Oncology, Laurence Zitvogel, M.D., Ph.D., Scientific Director, Gustave Roussy Cancer Centre, France

6 Concurrent Tracks

  • Intractable Targets/ Antibody Discovery Technologies
  • Bioinformatics / Repertoire
  • Antibody Effector Functions and Novel Formats
  • Novel Antibody-based Therapeutics for Cancer & Immuno-oncology
  • Antibodies Alternative Delivery/Vaccines
  • New Antibody Therapeutics in Inflammatory & Infectious Diseases

mabs

mabs

The Official Journal of The Antibody Society

Career Center

Our Career Center is a premier resource to connect highly qualified talent with matching career opportunities. Visit for details on over 800 jobs!

AIRR Community

AIRR Community

The Adaptive Immune Receptor Repertoire Community is a research-driven group organizing around the use of high-throughput sequencing technologies to study antibody/B-cell and T-cell receptor repertoires.

Recent Posts

  • The Society has selected mAbs as its Official Journal! July 29, 2022
  • Congratulations to our 2022 Antibody Research Competition winners! July 26, 2022
  • Register for our upcoming webinar on BLI and its use in anti-snake venom antibody discovery July 19, 2022

Archives

Follow us online

  • Email
  • LinkedIn
  • Twitter
  • YouTube
  • Home
  • Privacy & Terms of Use
  • About
  • Board of Directors
  • Advisors
  • Sponsors & Partners
  • Mission & Activities
  • Join the Society
  • Membership Levels
  • Members only
  • Login
  • Antibody therapeutics approved or in regulatory review in the EU or US
  • Meeting reports
  • Presentations
  • Contact

©2015 - scicomvisuals